Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN1920 in High-Risk Primary Membranous Nephropathy (China) – Phase IIa
CTR20254702Phase 2Active
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ALXN-1920 in idiopathic membranous glomerulonephritis (IMG), sponsored by Alexion Pharmaceuticals. Started Apr 2026; status: active.
02
Drugs
ALXN-1920
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on CTR20254702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254702.